Acadia Appoints Jim Daly To Board Of Directors

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Jim Daly has joined its Board of Directors. Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses.